Asrar Alahmadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asrar Alahmadi has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Adam M. Kresak
Division of Pathology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, Ohio
9 shared publications - Afshin Dowlati
University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
9 shared publications - Ahmad Perwez
Genome Biology Lab, Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi 110025, India
9 shared publications - Ashley M. Shay
Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, Ohio
9 shared publications - Ata Abbas
Case Western Reserve University 2 Cleveland, Ohio
9 shared publications - Gary Wildey
Division of Hematology and Oncology, Case Comprehensive Cancer Center and University Hospitals Case Medical Center, Cleveland, Ohio
9 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.
- Open Access
- 16 October 2026
- Published by MDPI AG in Preprints.org
Polygenic Risk Scores for Pancreatic Cancer Risk Prediction and Early Detection: A Systematic Evidence Review of Clinical Utility
Background/Objectives: Pancreatic cancer carries a five-year relative survival of 13%. Polygenic risk scores (PRS) rank inherited susceptibility across common variants. Prior syntheses pooled PRS association and discrimination, but none asked whether a PRS changes a clinical decision. We synthesized evidence on the clinical utility of PRS for pancreatic cancer risk assessment. Methods: In this PROSPERO-registered review (CRD42024511326), we searched four databases through May 11, 2026, for studies evaluating a PRS for primary pancreatic cancer risk in adults, alone or with clinical predictors. We recorded discrimination as the prerequisite for utility and organized utility across five prespecified domains: threshold-based accuracy, incremental value, calibrated absolute risk, decision-analytic output, and economic impact. We synthesized narratively and appraised risk of bias with PROBAST. Results: Forty-three studies met the inclusion and exclusion criteria, including 25 from the UK Biobank. Ten of 16 standalone discrimination estimates fell between 0.56 and 0.64. Adding PRS to a clinical model increased discrimination by at most 0.05 in general populations. Combined PRS and clinical models exceeded 0.80 only in three diabetes-focused studies. Six studies reported calibration, four reclassification, two decision-curve net benefit, none cost-effectiveness, and 20 had no translational milestone. Thirteen studies were at high risk of bias, with 11 in the analysis domain. Conclusions: Pancreatic cancer PRS discriminates modestly alone and adds most where prior risk is highest. Actionable use awaits an externally validated absolute-risk model with a prespecified threshold and a decision analysis.
- 16 October 2026
- Published by MDPI AG in Preprints.org
Open AccessPolygenic Risk Scores for Pancreatic Cancer Risk Prediction and Early Detection: A Systematic Evidence Review of Clinical Utility
Background/Objectives: Pancreatic cancer carries a five-year relative survival of 13%. Polygenic risk scores (PRS) rank inherited susceptibility across common variants. Prior syntheses pooled PRS association and discrimination, but none asked whether a PRS changes a clinical decision. We synthesized evidence on the clinical utility of PRS for pancreatic cancer risk assessment. Methods: In this PROSPERO-registered review (CRD42024511326), we searched four databases through May 11, 2026, for studies evaluating a PRS for primary pancreatic cancer risk in adults, alone or with clinical predictors. We recorded discrimination as the prerequisite for utility and organized utility across five prespecified domains: threshold-based accuracy, incremental value, calibrated absolute risk, decision-analytic output, and economic impact. We synthesized narratively and appraised risk of bias with PROBAST. Results: Forty-three studies met the inclusion and exclusion criteria, including 25 from the UK Biobank. Ten of 16 standalone discrimination estimates fell between 0.56 and 0.64. Adding PRS to a clinical model increased discrimination by at most 0.05 in general populations. Combined PRS and clinical models exceeded 0.80 only in three diabetes-focused studies. Six studies reported calibration, four reclassification, two decision-curve net benefit, none cost-effectiveness, and 20 had no translational milestone. Thirteen studies were at high risk of bias, with 11 in the analysis domain. Conclusions: Pancreatic cancer PRS discriminates modestly alone and adds most where prior risk is highest. Actionable use awaits an externally validated absolute-risk model with a prespecified threshold and a decision analysis.
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (11) , 1708-1720
Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (11) , 1708-1720
Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer
Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Incidence of brain metastases at diagnosis and prognosis according to lung cancer histology.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Incidence of brain metastases at diagnosis and prognosis according to lung cancer histology.
- 9 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (18) , 4463-4471
Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.
- 9 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (18) , 4463-4471
Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.
- Open Access
Hepatobiliary Progenitor-like Reprogramming in Liver Metastases
Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.
Open AccessHepatobiliary Progenitor-like Reprogramming in Liver Metastases
Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500521
Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R–Mutated Metastatic Pancreatic Adenocarcinoma
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500521
Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R–Mutated Metastatic Pancreatic Adenocarcinoma
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer